NovoCure Limited (NVCR) FY2026 YTD Q2 P&L / Income Statement

NovoCure Limited (NVCR) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

357,639,000 US dollars

Cost of revenues

80,035,000 US dollars

Gross profit

277,604,000 US dollars

Total operating costs and expenses

355,586,000 US dollars

Operating income (loss)

negative 77,982,000 US dollars

Other income (expense), net (calculated)

negative 3,728,000 US dollars

Income (loss) before income tax

negative 81,710,000 US dollars

Income tax

5,086,000 US dollars

Net income (loss)

negative 86,796,000 US dollars

UNITED STATES

198,911,000 US dollars

GERMANY

47,845,000 US dollars

FRANCE

44,225,000 US dollars

JAPAN

22,023,000 US dollars

Other international markets

33,884,000 US dollars

CHINA

10,751,000 US dollars

Research, development and clinical studies

109,784,000 US dollars

Sales and marketing

120,041,000 US dollars

General and administrative

125,761,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.